Tsuyuri generally refers to polyethylene glycolated recombinant human granulocyte stimulating factor injection, which is used to reduce the incidence of febrile neutropenia-induced infections in patients with non-myeloid malignancies receiving antineoplastic agents when there may be clinically significant febrile neutropenic myelosuppression. Polyethylene glycolated recombinant human granulocyte stimulating factor injection is not intended for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. Adverse reactions such as bone pain, arthralgia and muscle aches may occur with injection of this drug. It is contraindicated in severe hepatic, renal, cardiac and pulmonary dysfunction. Polyethylene glycolized recombinant human granulocyte stimulating factor injection has important clinical significance, and the drug is safe for short-term use, patients do not need to worry too much, and actively cooperate with doctors for treatment.